Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GLUE
MONTE ROSA THERAPEUTICS, INC.
NASDAQ
$13.38
▼ DOWN 6.56% (-0.94)

KEY STATISTICS

Market Cap$1.13 B
52w High$25.77
52w Low$4.60
Dividend Yield—
Frequency—
P/E-7.65
Volume884.55K
Shares Out.84.48M

COMPANY

LEADERSHIP

Markus Warmuth
CHIEF EXECUTIVE
Markus Warmuth

COMPENSATION 2026

Salary$650,000
Stock Awards$910,080
Incentive Plan Pay$429,000
All Other Comp.$0
Total$5,032,728

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 24, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
173

PRICE TARGET

Target High$28.00
Target Low$25.00
Target Median$27.00
Target Consensus$26.67

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$18.89M
NOV
5
THU

PRICE

$13.38 ▼ DOWN 6.56% (−$0.94)
$13.50$13.75$14.00$14.259:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM13.38

About Monte Rosa Therapeutics, Inc.

https://www.monterosatx.com ↗

Monte Rosa Therapeutics develops precision small molecule degraders targeting proteins like GSPT1, CDK2, NEK7, VAV1, and BCL11A for cancer, inflammatory, autoimmune, and hemoglobin disorder treatments.

INDUSTRY

Biotechnology

A PRODUCT MONTE ROSA THERAPEUTICS, INC. IS KNOWN FOR

MRT-6160
MRT-6160

MRT-6160 is an investigational VAV1-directed molecular glue degrader for immune diseases, developed under an exclusive license with Novartis, including $150M upfront and up to $2.1B in milestones.

COMPETITORS

COMPETITOR
ARVN COMPARE
BMY COMPARE
CCCC COMPARE
KYMR COMPARE
NRIX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
136
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.00% · 2.6M
XBI
0.27% · 2.3M
XSU.TO
0.03% · 1.9M
AVUV
0.02% · 523.9K
BSVO
0.19% · 351.0K
SCHA
0.02% · 327.6K
TMSL
0.13% · 269.0K
FESM
0.06% · 261.7K
DFAS
0.02% · 256.6K
FYC
0.23% · 231.0K
USVM
0.11% · 138.5K
LABU
0.18% · 81.9K
XRS2.F
0.03% · 67.8K
PRFZ
0.02% · 48.4K
JPSE
0.10% · 41.6K
RSSL
0.03% · 35.3K
GSSC
0.02% · 17.5K
BBC
0.47% · 17.2K
EES
0.03% · 13.5K
ETLZ.DE
0.04% · 6.7K
SQLV
0.15% · 4.2K
BIB
0.04% · 3.0K
TILT
0.00% · 2.8K
RFLR
0.03% · 2.4K
VETS
0.10% · 1.6K
USUE.DE
0.00% · 217

INSTITUTIONAL OWNERSHIP

SHARES OWNED
74.88%
HOLDERS
243
TOP 12 OF 243 · RANKED BY POSITION SIZE
Price T Rowe Associates Inc /Md/
8.9M sh · $214.44M
Nea Management Company, LLC
7.7M sh · $186.15M
Blackrock, Inc.
6.8M sh · $165.6M
Bvf Inc/Il
5.7M sh · $41.94M
Versant Venture Management, LLC
5.7M sh · $41.89M
Baker Bros. Advisors LP
4.9M sh · $36.43M
Tcg Crossover Management, LLC
4.6M sh · $72.48M
Vestal Point Capital, LP
4.6M sh · $111.32M
Suvretta Capital Management, LLC
4.2M sh · $69.53M
State Street Corp
3.7M sh · $90.3M
Vanguard Group Inc
3.2M sh · $50.91M
Braidwell LP
3.2M sh · $52.75M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT & CEO
Warmuth Markus
Sale · 9.5K shares
2026-07-16
★
OFFICER: CHIEF OPERATING OFFICER
Champoux Jennifer
Sale · 4.4K shares
2026-07-15
★
OFFICER: CHIEF OPERATING OFFICER
Champoux Jennifer
Purchase · 4.4K shares
2026-07-15
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Townson Sharon
Purchase · 6.0K shares
2026-07-06

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 3
BUY 1
OUTPERFORM 1
5 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY JP Morgan OVERWEIGHT Wells Fargo OVERWEIGHT Wedbush OUTPERFORM Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
VIR$10.83COMPARE
AVBP$30.17COMPARE
REPL$15.50COMPARE
MGTX$13.82COMPARE
GERN$1.51COMPARE
TBPH$17.05COMPARE
VALN$6.43COMPARE
ARVN$9.18COMPARE